论文部分内容阅读
目的观察依达拉奉对急性脑梗死的临床疗效。方法治疗组48例,在常规治疗的基础上加用依达拉奉治疗,对照组48例,仅用常规治疗方法。两组在治疗前、后14天分别进行神经功能缺损评分(ESS)和日常生活能力缺陷评分(ADL),同时两组均进行临床疗效评定。结果治疗组于治疗后ESS评分为(79.35±17.96)分、ADL评分为(73.02±25.60)分,均高于列照组(P<0.05);治疗组的显效率和有效率分别为47.91%和95.83%,显著高于对照组的20.83%和72.91%(P<0.05)。结论依达拉奉能有效改善急性脑梗死患者的神经功能缺失和日常生活能力。
Objective To observe the clinical effect of edaravone on acute cerebral infarction. Methods 48 cases of treatment group, based on conventional treatment with edaravone treatment, control group of 48 patients, only conventional treatment. Neurological deficit score (ESS) and daily living ability defect score (ADL) were evaluated in both groups before and 14 days after treatment, and the clinical efficacy was evaluated in both groups. Results The ESS score of the treatment group after treatment was (79.35 ± 17.96) points, ADL score was (73.02 ± 25.60) points, which were significantly higher than those of the control group (P <0.05). The effective rate and effective rate of the treatment group were 47.91% And 95.83% respectively, which was significantly higher than that of the control group (20.83% vs 72.91%, P <0.05). Conclusion Edaravone can effectively improve the neurological deficits and daily living ability of patients with acute cerebral infarction.